Jasper Therapeutics (JSPR) News Today $2.93 -0.02 (-0.68%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.98 +0.05 (+1.71%) As of 08/22/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period HC Wainwright Issues Pessimistic Outlook for JSPR EarningsAugust 19, 2025 | americanbankingnews.comWilliam Blair Issues Pessimistic Outlook for JSPR EarningsAugust 19, 2025 | americanbankingnews.comUBS Group Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $25.00August 18, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 17, 2025 | globenewswire.comBrokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75August 17, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 16, 2025 | prnewswire.comBTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)August 15, 2025 | theglobeandmail.comJasper Therapeutics price target lowered to $25 from $29 at UBSAugust 15, 2025 | msn.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deJasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)August 14, 2025 | msn.comJasper Therapeutics Reports Promising Q2 2025 ResultsAugust 14, 2025 | msn.comJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 6, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 1, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 31, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 22, 2025 | prnewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 17, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 14, 2025 | globenewswire.comHC Wainwright Issues Positive Estimate for JSPR EarningsJuly 14, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 12, 2025 | prnewswire.comJSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJuly 11, 2025 | businesswire.comJasper Therapeutics Announces Corporate Reorganization and Other Cost ...July 11, 2025 | morningstar.comMJasper Therapeutics Announces 50% Workforce Reduction and ... - NasdaqJuly 11, 2025 | nasdaq.comUBS Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)July 9, 2025 | theglobeandmail.comJasper Therapeutics, Inc.: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9, 2025 | finanznachrichten.deJasper Therapeutics Cutting Half of Staff After Study SetbackJuly 9, 2025 | marketwatch.comJasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Given Market Perform Rating at BMO Capital MarketsJuly 8, 2025 | marketbeat.comJasper Therapeutics Inc News (JSPR) - Investing.comJuly 8, 2025 | investing.comCantor Fitzgerald Downgrades Jasper Therapeutics (JSPR)July 8, 2025 | msn.comJasper Therapeutics (NASDAQ:JSPR) Lowered to "Neutral" Rating by Cantor FitzgeraldJuly 7, 2025 | marketbeat.comJasper Therapeutics Shares Fall On Briquilimab Drug Lot ProblemJuly 7, 2025 | benzinga.comJasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous UrticariaJuly 7, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from BrokeragesJune 25, 2025 | marketbeat.comJasper Therapeutics stock maintains buy rating on positive urticaria dataJune 18, 2025 | investing.comJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible UrticariaJune 15, 2025 | nasdaq.comJasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinizedJune 15, 2025 | investing.comJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJune 14, 2025 | globenewswire.comAnalysts Offer Predictions for JSPR FY2026 EarningsJune 10, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressJune 3, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by BrokeragesJune 1, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyMay 29, 2025 | finance.yahoo.com Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼-0.750.71▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼93▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies China SXT Pharmaceuticals News Caribou Biosciences News C4 Therapeutics News Tevogen Bio News SELLAS Life Sciences Group News Enanta Pharmaceuticals News Lifevantage News Actuate Therapeutics News Nkarta News Nuvectis Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access